#USA #Wilmington #DeepCyte #DeeTox Atlas #Drug Toxicity

DeepCyte Launches the Groundbreaking DeeTox Atlas™

In a groundbreaking move for drug development, DeepCyte Inc., a pioneering techbio company, has announced the launch of DeeTox Atlas™, the world's first single-cell metabolomic reference atlas dedicated to drug toxicity mechanisms. This revolutionary tool positions the company at the forefront of transforming preclinical toxicology, making significant strides in the pharmaceutical industry.

What is DeeTox Atlas™?

DeeTox Atlas™ is not just another dataset; it represents a comprehensive foundation built upon two independent single-cell metabolomics perturbation studies, encompassing around 100 toxic compounds and 300,000 cells. Each cell provides insights into approximately 500 metabolites—a staggering 3,000 single-cell measurements per compound averaged across six biological replicates. The beauty of DeeTox Atlas™ lies in its detailed mapping of each compound against a curated hierarchy of toxicity mechanisms, anchored on established Adverse Outcome Pathways (AOPs).

The unique capability of DeepCyte's model allows it to predict toxicity mechanisms for compounds without new wet-lab data. By fostering their foundation model, they ensure that as the atlas evolves, its predictive accuracy does not only improve but also scales effectively, consequently minimizing reliance on labor-intensive laboratory experiments.

The AI Approach in Toxicology

DeepCyte's CEO and Co-Founder, Theodore Alexandrov, emphasized the paradigm shift that DeeTox Atlas™ brings to toxicology. He noted, "AI in toxicology is only as good as the biological data it learns from. DeeTox Atlas enables us to uncover subtle molecular patterns associated with key toxicity mechanisms—patterns often expressed in minor subpopulations of cells. These subtleties can remain undetected through traditional methods lacking single-cell resolution."

The DeeTox Atlas aims to revolutionize the way toxicologists, medicinal chemists, and safety scientists approach prediction and analysis in drug discovery. By shifting towards mechanism-based AI, the technology promises increased efficiency in surfacing and explaining safety concerns earlier in the drug development cycle.

Future Directions and Enterprise Partnerships

Alongside the launch, DeepCyte is embarking on pilot programs with three of the top 20 pharmaceutical companies, indicating strong interest from industry giants in adopting this innovative approach. The atlas will continue to grow, incorporating more compounds, mechanisms, and an array of biochemical and clinical data, thereby enhancing its applicability and predictive capabilities.

To lead the commercialization efforts of this groundbreaking technology, DeepCyte has appointed Mona Lakkis as Senior Vice President of Partnerships. With her extensive background, including her tenure as Senior Vice President and General Manager at Owkin, Lakkis is poised to guide the enterprise's trajectory as they pursue these pilot initiatives.

About DeepCyte

DeepCyte stands out as an AI-driven techbio company dedicated to developing predictive toxicology solutions tailored for drug discovery processes. By leveraging mechanistic AI models trained on proprietary single-cell datasets, DeepCyte assists pharmaceutical companies in earlier predictions of toxicity mechanisms, ultimately expediting the discovery of safer and more effective therapeutics.

In conclusion, the introduction of DeeTox Atlas™ marks a significant milestone not just for DeepCyte, but for the entire field of pharmaceutical development. It embodies the convergence of advanced technology and rigorous science, paving the way for a more predictive and efficient future in drug safety and effectiveness assessment.